Atlas
Back to RCM
Investment Banker·RCM

Grant Chamberlain

Senior Managing Director, Healthcare IT Investment Banking at Ziegler

Chicago, Illinois

GC
LinkedIn
Why they matter

Chicago banker who has sold telehealth and HCIT assets for 25+ years; deep sell-side coverage of reimbursement-driven provider tech, plus an ATA board seat shaping policy.

Background

Grant Chamberlain is Senior Managing Director in Ziegler's Healthcare Investment Banking Practice, based in the firm's Chicago office, which he joined in 2015. He has over 25 years of investment banking experience concentrated on healthcare IT and tech-enabled outsourced services, and previously led mHealth sector coverage at Raymond James after serving as a principal at Shattuck Hammond Partners (acquired by Morgan Keegan) and working in GE Capital's corporate finance group and the financial services division of GE Medical Systems. He sits on Ziegler's Healthcare IT team, whose stated coverage spans telemedicine, managed care, provider and payor outsourcing, and revenue cycle management, and has closed 15+ physician practice management deals concentrated in oncology.

Notable deals

  • 2025
    Lead banker on Ziegler's engagement as exclusive financial advisor to Xealth, a digital health integration platform spanning 500+ US hospitals, on its sale to Samsung Electronics.
  • 2025
    Co-led Ziegler as exclusive financial advisor to MD Revolution, a remote care management software and clinical services platform integrated with 35+ EHRs, on its sale to CoachCare.
  • 2024
    Part of the Ziegler team advising multi-specialty telemedicine provider TeleMed2U on its majority investment from Kayne Anderson Growth Capital.
  • 2022
    Advised CancerIQ on a $14 million Series B private placement led by Merck Global Health Innovation Fund and Amgen Ventures, with McKesson Ventures and OSF Ventures participating.

Call-prep brief

Background

  • 25+ years in healthcare investment banking; joined Ziegler in 2015, now Senior Managing Director, Healthcare Investment Banking, Chicago.
  • Prior: led mHealth coverage at Raymond James; principal at Shattuck Hammond Partners (acquired by Morgan Keegan); GE Capital corporate finance and GE Medical Systems financial services. B.A. in finance, University of Wisconsin-Madison.

Current focus

  • Sell-side M&A and growth capital for telehealth, remote patient monitoring, and tech-enabled provider/payor outsourcing. Sits inside Ziegler's Healthcare IT practice, whose stated coverage includes revenue cycle management.
  • Separately, 15+ closed physician practice management deals, concentrated in oncology.

What he cares about

  • Reimbursement durability. On the MD Revolution sale he argued the remote care sector "is in desperate need of scaled platforms with the flexibility to react to the ever-changing reimbursement landscape" — a fair proxy for how he underwrites RCM-adjacent assets.
  • Policy: elected Director of the ATA and board member of ATA Action; also on the board of The MAVEN Project.

Recent moves

  • Xealth to Samsung Electronics (Nov 2025), lead banker.
  • MD Revolution to CoachCare (Jun 2025).
  • TeleMed2U majority investment from Kayne Anderson Growth Capital (Mar 2024).

Potential sensitivities

  • He is a sell-side agent. Assume anything he offers on a live process is positioning, and expect him to decline on client names, valuations, and mandates.
  • His core franchise is virtual care and HCIT, not pure-play RCM. Treat him as a channel into reimbursement-exposed provider tech rather than a coding/denials specialist.
  • His ATA advocacy role may make him guarded about attributable policy speculation.

Three questions to ask

  1. Which RCM-adjacent assets in your pipeline are being repriced by denials automation and AI coding, and what multiples are actually clearing?
  2. Where does virtual care revenue integrity overlap with the traditional RCM buyer set — are strategics or sponsors winning those?
  3. Post-Xealth, how is a buyer like Samsung changing who competes for provider-workflow software?

Outreach draft

Subject
Reimbursement-exposed provider tech: 20 minutes?
Grant — I lead healthcare technology investing at [Firm], and we are building conviction in revenue cycle and reimbursement-exposed provider software. Your comment on the MD Revolution sale, that remote care needs scaled platforms flexible enough to absorb reimbursement change, is close to our own thesis, and the Xealth sale to Samsung suggests the strategic buyer set is widening faster than most sponsors assume. We are not running a process and would not ask you to break a confidence. I would value 20 minutes on where denials automation and coding AI are repricing assets, and which subsectors you think are mispriced heading into next year. Happy to work around your calendar. Best, [Your Name] [Title], [Firm]

Linked companies

Sources